This issue covers a notably busy fortnight for regulatory-affairs teams. In the US, FDA has issued a batch of de novo-style Class II classification orders spanning cardiovascular AI, ablation-protection devices, a urinary continence implant, and more — each carrying its own special controls that will shape future 510(k) pathways. In the UK, the National Commission on the Regulation of AI in Healthcare has published its framework recommendations, the MHRA has launched a health-innovation sandbox with Manchester NHS, and two consecutive weeks of Field Safety Notices demand vigilance. We also flag updated human-factors expectations inside FDA's eSTAR and a Health Canada forms update for teams with Canadian market access obligations.
UK National Commission Publishes AI-in-Healthcare Regulatory Framework Recommendations
MHRA · UK
This is the most significant UK policy signal of the fortnight for teams developing AI-enabled medical devices. The National Commission's recommendations will directly inform MHRA's future regulatory framework for AI in healthcare, potentially reshaping conformity-assessment routes, post-market surveillance obligations, and transparency requirements under UKCA. RA leaders should review the recommendations now to anticipate upcoming regulatory changes and feed into any forthcoming MHRA consultation.
Read the source →FDA Classifies Cardiovascular Machine Learning-Based Notification Software as Class II (Special Controls)
FDA · US
This classification order, effective 11 September 2026, establishes the regulatory pathway and mandatory special controls for cardiovascular ML notification software — a growing device category. Any manufacturer developing or planning a 510(k) for this type of AI/ML-driven software must now comply with these special controls. The order also signals FDA's broader intent to systematically classify AI-powered cardiovascular tools, providing a clearer (if more demanding) market-access route.
Read the source →FDA Issues Wave of Class II Classification Orders Across Multiple Device Categories (Effective 10 September 2026)
FDA · US
In a single day, FDA issued Class II (special controls) classification orders for six distinct device types: mechanical and temperature-regulation devices for esophageal protection during cardiac ablation, extravascular AV fistula support, anti-TNFα monoclonal antibody test systems for IBD, cooperative powered surgical assist devices for ENT, implanted tibial electrical urinary continence devices, vaginal hydrogel packing systems, and whole-room microbial reduction devices. Each classification creates new 510(k) predicate pathways and imposes bespoke special controls. Teams with products in or adjacent to any of these categories should urgently review the relevant orders to assess submission strategy, labelling, and performance-testing requirements.
Read the source →MHRA & Manchester NHS Launch Health Innovation Sandbox for AI and New Technologies
MHRA · UK
The new MHRA–Manchester NHS sandbox offers manufacturers a structured environment to generate real-world evidence for novel technologies — including AI devices — under regulatory oversight, prior to full UKCA conformity assessment. For SMEs and consultancies advising clients on UK market access, this is a tangible early-access route worth monitoring for eligibility criteria and application windows. It also signals MHRA's continued intent to be a pro-innovation regulator post-Brexit.
Read the source →FDA eSTAR: Human Factors Documentation Now a Substantive Submission Requirement — Not a Checkbox
INDUSTRY · GLOBAL
FDA's eSTAR framework has materially raised the bar for how use-related risk and human factors validation must be documented in premarket submissions. Teams preparing 510(k)s or De Novos who treat human factors as a late-stage formality risk rejection or additional information requests. RA leaders should audit their human-factors integration processes against eSTAR requirements now, particularly for combination products and software-driven devices where use errors carry elevated risk.
Read the source →MHRA Field Safety Notices: Two Consecutive Fortnights (24 Aug–4 Sep & 7–11 Sep 2026)
MHRA · UK
Back-to-back FSN summary publications from MHRA are essential reading for post-market surveillance and vigilance teams. Manufacturers and distributors must check whether any notices relate to their device categories, assess reportability obligations under UK MDR 2002 (as amended), and update their vigilance files accordingly. Consultancies should ensure clients on UK PRRC arrangements are aware of both batches promptly.
Read the source →MHRA Safety Alert: Filters Mandatory for Parenteral Nutrition Administration in All Care Settings (DSI/2026/011)
MHRA · UK
MHRA has issued a Device Safety Information notice (DSI/2026/011) confirming that administration of parenteral nutrition without an inline filter has caused serious adverse incidents, including a fatal embolism. Manufacturers of parenteral nutrition delivery systems, infusion sets, and associated filters should review their labelling, instructions for use, and post-market clinical follow-up data to ensure compliance. Distributors and healthcare procurement teams supplying UK markets should also check conformance with this alert.
Read the source →Health Canada Updates Forms for Exceptional Importation and Sale of Medical Devices
Health Canada · CA
Teams managing multi-market portfolios that include Canada must update their exceptional importation/sale submissions to use the revised Health Canada forms immediately. Using outdated forms risks processing delays or rejection. This is especially relevant for SMEs supplying specialist or shortage devices to the Canadian market under exceptional access provisions.
Read the source →